REFORM is indicated to treat type-2 diabetes.
Mode of Action
REFORM decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting plasma insulin levels and day-long plasma insulin response may actually decrease. It is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
REFORM is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. It is excreted unchanged in the urine and does not undergo hepatic metabolism or biliary excretion.
Dosage and Recommendation
Initial dose: 500 mg orally twice a day or 850 mg orally once a day Dose titration: Increase in 500 mg weekly increments or 850 mg every 2 weeks as tolerated Maintenance dose: 2000 mg daily Maximum dose: 2550 mg daily
Packing and Presentation
REFORM 500/850/1000 are available as a blister strip of 10 tablets in a box of 10 x 10s